NYSEAMERICAN:SYN Synthetic Biologics (SYN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Synthetic Biologics Stock (NYSEAMERICAN:SYN) Get Synthetic Biologics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,700 shsAverage Volume197,338 shsMarket Capitalization$16.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Synthetic Biologics, Inc. is a clinical‐stage biopharmaceutical company headquartered in Rockville, Maryland, focused on developing novel therapies to prevent and treat serious bacterial infections by preserving the integrity of the gut microbiome. The company’s research platform leverages enzyme and microbiome modulation technologies to counteract the unintended consequences of antibiotic therapies, aiming to reduce the incidence of Clostridioides difficile infection and other antibiotic‐associated complications. The company’s lead product candidate, ribaxamase (SYN-004), is an orally administered beta‐lactamase enzyme designed to degrade certain intravenous beta‐lactam antibiotics in the gastrointestinal tract, thereby protecting the gut from antibiotic‐induced dysbiosis. Ribaxamase has been evaluated in multiple clinical trials, including studies in patients undergoing treatment for serious infections such as pneumonia. Synthetic Biologics has also been advancing additional pipeline programs that explore microbiome‐based approaches for gastrointestinal and metabolic disorders. Synthetic Biologics collaborates with pharmaceutical partners to facilitate global development and commercialization, having secured agreements to support late‐stage studies and future market access. The company is led by President and Chief Executive Officer William H. Martin, under the guidance of an experienced board with deep expertise in biopharmaceutical research and development. Synthetic Biologics is committed to innovating solutions that address critical unmet needs in infectious disease and gastrointestinal health.AI Generated. May Contain Errors. Read More Receive SYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYN Stock News HeadlinesActive Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030 with 6.6% CAGR | MarketsandMarkets™October 15 at 2:53 PM | finance.yahoo.comProtein Expression Market to Hit USD 6.60 Billion by 2032 on Rising Biologics and Personalized Medicine Demand | S&S InsiderSeptember 26, 2025 | finance.yahoo.com$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.October 17 at 2:00 AM | Weiss Ratings (Ad)Synthetic Darwin and Star26 Capital Partner to Advance Defense AIJuly 16, 2025 | tmcnet.comThe Hidden Downside Of Synthetic Stone CountertopsJuly 16, 2025 | msn.comMost Major Ice Cream Brands Will Remove Synthetic Dyes by 2028July 15, 2025 | usnews.comSynthetic Dyes Present in 19 Percent of U.S. Food ProductsJuly 4, 2025 | msn.comFlexiteek Expands Synthetic Decking Line with New Tritone FinishJuly 3, 2025 | msn.comSee More Headlines SYN Stock Analysis - Frequently Asked Questions How were Synthetic Biologics' earnings last quarter? Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) announced its earnings results on Tuesday, November, 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. When did Synthetic Biologics' stock split? Synthetic Biologics's stock reverse split before market open on Monday, July 25th 2022.The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Synthetic Biologics? Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Meta Platforms (META). Company Calendar Last Earnings11/02/2021Today10/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:SYN CIK894158 Webwww.syntheticbiologics.com Phone(301) 417-4364Fax301-417-4367Employees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.14% Return on Assets-22.74% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / BookN/AMiscellaneous Outstanding Shares15,844,000Free Float15,503,000Market Cap$16.16 million OptionableNot Optionable Beta1.38 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSEAMERICAN:SYN) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synthetic Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
